Emergent BioSolutions (EBS) to Post Earnings on Wednesday

Emergent BioSolutions (NYSE:EBS - Get Free Report) is projected to release its Q1 2025 earnings data after the market closes on Wednesday, May 7th. Analysts expect Emergent BioSolutions to post earnings of $0.71 per share and revenue of $218.50 million for the quarter. Emergent BioSolutions has set its FY 2025 guidance at EPS.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.35) by $0.40. The business had revenue of $194.70 million during the quarter, compared to analysts' expectations of $254.67 million. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. During the same period last year, the company posted ($0.77) earnings per share. On average, analysts expect Emergent BioSolutions to post $-1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Emergent BioSolutions Stock Performance

Shares of Emergent BioSolutions stock traded down $0.12 during trading on Monday, reaching $5.03. The company's stock had a trading volume of 123,502 shares, compared to its average volume of 1,970,317. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The firm has a market cap of $273.04 million, a price-to-earnings ratio of -1.23 and a beta of 2.14. The business's fifty day moving average price is $5.31 and its 200-day moving average price is $8.04. Emergent BioSolutions has a one year low of $3.84 and a one year high of $15.10.

Emergent BioSolutions declared that its Board of Directors has initiated a stock repurchase plan on Monday, March 31st that permits the company to buyback $50.00 million in outstanding shares. This buyback authorization permits the biopharmaceutical company to reacquire up to 19% of its shares through open market purchases. Shares buyback plans are usually a sign that the company's leadership believes its stock is undervalued.

Insider Buying and Selling

In related news, Director Neal Franklin Fowler sold 35,000 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total transaction of $204,050.00. Following the sale, the director now owns 101,100 shares of the company's stock, valued at approximately $589,413. This represents a 25.72 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on EBS. StockNews.com cut Emergent BioSolutions from a "buy" rating to a "hold" rating in a report on Wednesday, March 5th. HC Wainwright reissued a "buy" rating and issued a $15.00 price target on shares of Emergent BioSolutions in a report on Tuesday, April 1st.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.